3 ratings / 4.67 average

New Therapies for Diffuse Large B Cell Lymphoma

Zahid Bashir1,2 and Andrew John Davies3


Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease with specific subtypes and morphological variants [1]. No single genetic abnormality is diagnostic of DLBCL; however, gene-expression profiling identifies germinal center B cell-like (GCB) and activated B cell-like (ABC) as two distinct subtypes, providing important diagnostic and prognostic information (

  • Figure1
). Patients identified as having the ABC subtype have a 5-year overall survival (OS) rate of 30%, compared with an almost 60% 5-year OS rate in the GCB subgroup [2,3].

Return to top

LATEST ARTICLES